Our top pick for
Ovintiv Inc is an other business based in the US. Ovintiv shares (ECA) are listed on the NYSE and all prices are listed in US Dollars.
|52-week range||$0.00 - $0.00|
|50-day moving average||$14.38|
|200-day moving average||$20.32|
|Wall St. target price||$28.55|
|Dividend yield||$0.38 (11.4%)|
|Earnings per share (TTM)||$0.90|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Ovintiv stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ovintiv's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ovintiv's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Ovintiv shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ovintiv's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ovintiv's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ovintiv's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.8 billion.
The EBITDA is a measure of a Ovintiv's overall financial performance and is widely used to measure a its profitability.
|Gross profit TTM||$3.5 billion|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$981.9 million|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ovintiv.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 40.51
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ovintiv's overall score of 40.51 (as at 12/31/2018) is pretty weak – landing it in it in the 75th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Ovintiv is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 22.83/100
Ovintiv's environmental score of 22.83 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Ovintiv is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.23/100
Ovintiv's social score of 13.23 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Ovintiv is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 11.45/100
Ovintiv's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Ovintiv is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Ovintiv scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Ovintiv has, for the most part, managed to keep its nose clean.
|Total ESG score||40.51|
|Total ESG percentile||75.44|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
We're not expecting Ovintiv to pay a dividend over the next 12 months.
Ovintiv Inc. , together with its subsidiaries, engages in the exploration, development, and production of natural gas, oil, and natural gas liquids (NGLs) in the United States and Canada. Its properties in the United States include Permian in west Texas and Anadarko in west-central Oklahoma; and other upstream operations comprise Eagle Ford in south Texas, Bakken in North Dakota, and Uinta in central Utah. The company's properties in Canada comprise Montney in northeast British Columbia and northwest Alberta; and other upstream operations comprise Duvernay in west central Alberta, Wheatland in southern Alberta, Horn River in northeast British Columbia, and Deep Panuke located offshore Nova Scotia. It is also involved in the marketing of oil, NGLs, and natural gas. Ovintiv Inc. is based in Denver, Colorado.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.